The failure rate of new drugs for glioblastoma (GBM, form of brain cancer) is about 99% or higher. Recurrence and mortality of GBM and other solid tumor cancers develops from highly resistant stem cell phenotypes that remain after primary treatment. Currently there are no adequate tools to study these lethal cell phenotype populations. Our company has developed a platform of diagnostic tools to study these cell phenotypes. Now, drug development companies can test their drugs and compounds to see if they affect stem cell phenotypes in addition to primary tumor cells. If drugs or compounds are effective in killing or stopping both primary tumor cells and stem cell phenotypes, there is a much greater chance of having a successful drug candidate that will make a difference in patients' lives.